NCT04575311

A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Arcus Biosciences, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers.

Detailed description

The study will evaluate minimum of 2 dose levels of AB680 in 8 participants per cohort. Cohorts will be gender-balanced to the extent possible, and will be randomized 3:1, active vs placebo, respectively. The participants will be closely observed for the first 48 hours following drug administration to monitor the general tolerability of AB680.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	AB680	AB680 is a Cluster of Differentiation (CD)73 Inhibitor
OTHER	Placebo	Matching Placebo

Timeline

• Start date: 2020-10-20
• Primary completion: 2021-09-22
• Completion: 2021-09-22
• First posted: 2020-10-05
• Last updated: 2024-05-24

Locations

1 site across 1 country: Australia